Zilovertamab vedotin
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Acute Lymphoblastic Leukemia
Conditions
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma
Trial Timeline
Aug 16, 2024 → Mar 31, 2029
NCT ID
NCT06395103About Zilovertamab vedotin
Zilovertamab vedotin is a phase 1/2 stage product being developed by Merck for B-cell Acute Lymphoblastic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06395103. Target conditions include B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma.
What happened to similar drugs?
3 of 20 similar drugs in B-cell Acute Lymphoblastic Leukemia were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06395103 | Phase 1/2 | Recruiting |
| NCT05144841 | Phase 2 | Active |
| NCT04504916 | Phase 2 | Terminated |
| NCT03833180 | Phase 1 | Completed |
Competing Products
20 competing products in B-cell Acute Lymphoblastic Leukemia